Customized galactose-conjugated LNP development services for ASGPR-mediated hepatocyte delivery, ligand density optimization, payload-compatible formulation screening, and surface characterization from ligand synthesis to cell-based evaluation.
Galactose-conjugated lipid nanoparticles (LNPs) carry galactose-based ligands on the particle surface. Terminal galactose residues are recognized by the asialoglycoprotein receptor (ASGPR), a C-type lectin expressed at high levels on hepatocytes—on the order of several hundred thousand copies per cell in common research models. ASGPR binds galactose-terminated glycoconjugates, internalizes them through clathrin-mediated endocytosis, and then recycles back to the cell surface within minutes. This fast recycling cycle makes ASGPR one of the most efficient uptake portals available for liver-directed delivery research.
Conventional LNPs rely largely on adsorbed apolipoproteins and LDL receptor-mediated uptake in the liver. That pathway can become unreliable when apolipoprotein adsorption is weak or when LDL receptor expression is low in the chosen disease model. Decorating the LNP surface with galactose, lactobionic acid, or galactose clusters provides a receptor-directed route that does not depend on the ApoE-LDLR axis, which is why galactose modification remains a workhorse strategy in hepatocyte-targeted delivery studies.
Our services cover galactose ligand selection, galactose-lipid synthesis, surface functionalization, formulation co-optimization, physicochemical and surface characterization, and ASGPR-related hepatocyte delivery evaluation.
Galactose-Modified LNP Structure IllustrationBOC Sciences supports the full development workflow from galactose ligand selection and lipid conjugate synthesis to LNP preparation, surface characterization, and ASGPR-related hepatocyte delivery evaluation.
We help select the galactose ligand format that fits your payload, target cell model, and modification route, then synthesize the corresponding galactose-lipid conjugates.
Galactose display only translates into hepatocyte uptake when the ligand is reachable and present at a workable density. We optimize both variables together rather than in isolation.
Adding galactose-lipids changes the self-assembly environment of the LNP. We rebalance the core formulation so that surface modification does not come at the cost of payload loading.
We characterize galactose-modified LNPs to confirm that the ligand is actually on the particle, at the intended level, and that the particle survived the modification.
We test whether the galactose layer produces receptor-directed delivery, using control designs that separate ASGPR-mediated uptake from generic nanoparticle uptake.
BOC Sciences supports process development so that galactose-LNP candidates prepared in screening can be reproduced in later preparations with consistent quality.
The galactose ligand reaches the LNP surface through a lipid anchor, and the choice of anchor—phospholipid or cholesterol, with or without a PEG spacer—changes how the ligand behaves. BOC Sciences develops all four common architectures and helps select between them based on the target density, the payload, and how much surface restructuring the LNP can tolerate.
Galactose or lactobionic acid is coupled directly to a phospholipid headgroup, typically DSPE or DSPC, and incorporated into the LNP as a structural lipid.
Galactose is attached to DSPE through a PEG spacer, lifting the ligand above the PEG brush and giving the headgroup room to move.
Galactose is coupled to a cholesterol anchor and integrated into the LNP shell alongside the formulation's free cholesterol.
Galactose-PEG-cholesterol conjugates combine a cholesterol anchor with a PEG spacer for elevated display without adding phospholipid character to the shell.
Tell us your preferred galactose structure, lipid anchor, PEG spacer, payload, and target cell model. We can help plan conjugate synthesis and compatible LNP formulation screening.
There is more than one way to put galactose on an LNP, and the route matters as much as the ligand. BOC Sciences develops all four common routes and selects between them according to the payload, the base formulation, and the target ligand density.
The galactose-lipid conjugate is dissolved together with ionizable lipid, helper lipids, cholesterol, and PEG-lipid in the organic phase, and the LNP self-assembles around the payload in a single step.
Galactose-lipid micelles are incubated with preformed LNPs under controlled temperature and mixing conditions, and the conjugate inserts into the outer leaflet of the particle shell.
Thiol-bearing galactose ligands react with maleimide-functionalized PEG-lipids on the LNP surface to form a stable thioether linkage.
Azide-functionalized galactose ligands react with DBCO-bearing lipids on the LNP surface through strain-promoted azide-alkyne cycloaddition, without copper catalysts.
Galactose modification gives LNPs a defined entry route into hepatocytes and keeps the surface chemistry small, synthetic, and controllable. The four advantages below explain why this strategy continues to anchor so much liver-directed delivery research.
ASGPR is expressed predominantly on hepatocytes and is designed by nature to capture galactose-terminated molecules, internalize them through clathrin-coated pits, and recycle to the surface within roughly 15 minutes. A galactose-decorated LNP that engages this receptor gains access to a high-capacity, hepatocyte-selective uptake pathway that does not depend on apolipoprotein adsorption or LDL receptor expression. In research models where the ApoE-LDLR axis is unreliable, this receptor-directed route often restores hepatocyte delivery rather than merely improving it.
ASGPR recognizes individual galactose residues weakly, but multiple receptor-ligand interactions acting together produce strong apparent binding. That gives formulators a real dial to turn: galactose-lipid fraction, spacer length, and clustered display can each be adjusted to move the formulation along the curve from too-sparse to oversaturated. Because the optimum sits in a window rather than at a maximum, density screening with proper controls reliably identifies the useful range for a given payload and particle size.
Galactose surface modification is compatible with the payload classes already used in LNP research: siRNA and antisense oligonucleotides, mRNA and self-amplifying RNA, gRNA/mRNA editing complexes, peptides, small molecules, and imaging tracers. Because the modification happens at the particle shell, the encapsulation strategy for the payload core can usually be preserved. Teams running several payload types can often carry one galactose surface architecture between programs with only density and spacer adjustments.
Galactose is a small, fully synthetic ligand. Galactose-lipid conjugates are prepared by carbohydrate chemistry rather than biological expression, which makes them straightforward to characterize by HPLC and mass spectrometry and consistent from batch to batch. The ligand is also neutral and compact, so it integrates into standard microfluidic and ethanol-dilution workflows without forcing a redesign of the ionizable lipid system.
BOC Sciences develops galactose-modified LNPs for the payload classes used in hepatocyte-directed delivery research. Each payload type needs its own loading strategy and functional readout, and we match the galactose surface design to both.
| Payload Type | Supported Uses & Galactose-LNP Development Considerations | Request Information |
|---|---|---|
| Galactose-LNP Development for siRNA and ASO | Suitable for hepatocyte gene-silencing studies, metabolic pathway research, and inflammatory target knockdown. Development focuses on encapsulation efficiency, free RNA reduction, galactose density, ASGPR-dependent uptake, and knockdown comparison against matched unmodified LNPs, building on our LNPs for siRNA delivery and ASO delivery capabilities. | Inquiry |
| Galactose-LNP Development for mRNA and Self-Amplifying RNA | Designed for hepatocyte protein expression studies, reporter systems, and formulation comparison. Development considers RNA integrity, encapsulation, galactose exposure, particle stability, and expression readouts in hepatocyte-lineage models, supported by our experience in LNPs for mRNA delivery. | Inquiry |
| Galactose-LNP Development for gRNA/mRNA Combination | Supports co-loaded gene editing systems that need ratio control and particle uniformity. We evaluate co-encapsulation behavior, galactose-lipid compatibility, particle attributes, and editing-related readouts under matched control conditions. | Inquiry |
| Galactose-LNP Development for Peptide and Protein | Suitable for enzyme replacement research payloads, binding proteins, and functional peptides directed to hepatocytes. Formulation work focuses on mild loading conditions, aggregation control, and activity retention after galactose modification. | Inquiry |
| Galactose-LNP Development for Small Molecules | Designed for hydrophobic and amphiphilic compounds used in liver disease research, including anti-inflammatory and metabolic pathway modulators. We consider drug-lipid compatibility, loading method, leakage control, and post-modification retention, drawing on our LNPs for small-molecule delivery experience. | Inquiry |
| Galactose-LNP Development for Fluorescent and Imaging Payloads | Supports fluorescent dyes, labeled RNA, and tracking payloads used to study hepatocyte uptake, intracellular localization, and liver distribution trends in formulation comparison studies. | Inquiry |
| Galactose-LNP Development for Custom Payload | Developed for unusual payloads, dual-payload systems, and early feasibility studies. We evaluate payload compatibility, loading sequence, galactose modification route, and target-cell delivery performance. | Inquiry |
Galactose-LNP projects usually stall in predictable places: the ligand is present but not reachable, the particle degraded during modification, or uptake improved while payload function did not. BOC Sciences works through these issues with data rather than guesswork.
A galactose-LNP can fail to outperform the unmodified control when the ligand sits too close to the surface or is buried under the PEG brush. We screen spacer length, anchor structure, ligand density, and PEG-lipid ratio together, and verify improvements with receptor competition assays rather than total fluorescence alone.
Feed ratio does not equal surface density. We measure actual galactose display using lectin binding and chromatographic methods, compare feed versus measured density across modification routes, and adjust the incorporation strategy until the intended density is achieved reproducibly.
Adding sugar-bearing lipids can disturb shell packing and trigger size growth or aggregation. We rebalance helper lipid, cholesterol, and PEG-lipid content around the galactose-lipid, switch anchors where needed, and monitor serum stability so the modified particle stays within your target size window.
Surface modification competes with payload loading for the same assembly process. We optimize lipid composition, aqueous phase conditions, and process parameters for encapsulation, and track retention after modification through encapsulation efficiency optimization and payload retention testing.
Total liver fluorescence can look convincing while the payload sits in Kupffer cells and sinusoidal endothelium instead of hepatocytes. We design matched controls, cell-type-relevant uptake models, and distribution readouts that distinguish parenchymal from nonparenchymal uptake, so the formulation is judged on the right cell population.
Strong uptake with weak knockdown or expression usually points to release, not binding. We evaluate RNA integrity, intracellular localization, and endosomal release, supported by LNP endosomal escape evaluation, to locate the real bottleneck between the surface and the cytosol.
BOC Sciences helps research teams troubleshoot ligand exposure, density control, particle instability, nonparenchymal uptake, and the gap between uptake and payload function.
We start by discussing your payload, target cell model, delivery goal, preferred readouts, and expected LNP attributes. We also review whether your project centers on primary hepatocytes, hepatocyte-lineage cell models, or liver distribution studies, and whether a GalNAc comparison branch is planned. From these details, BOC Sciences prepares a practical galactose-LNP development plan with clear decision points.
We design the galactose surface architecture around your payload and model. The design covers ligand format, such as galactose, lactobionic acid, or clustered display, along with PEG spacer length, lipid anchor, target density range, and the modification route—co-assembly, post-insertion, thiol-maleimide, or copper-free click. Where several routes are viable, we lay out the trade-offs so the choice is made with eyes open.
BOC Sciences prepares galactose-LNP candidates and matched unmodified controls. During LNP process optimization, we adjust lipid composition, payload loading, mixing conditions, buffer exchange, and ligand density, iterating until particle quality, galactose display, and payload retention all meet the project targets.
Each candidate is characterized for size, PDI, zeta potential, payload loading, and surface galactose density. We then run nanoparticle cellular uptake testing with receptor competition designs, followed by functional readouts—knockdown, expression, or activity—that tell you whether the galactose layer actually earned its place on the particle.
Whether you are investigating a hepatic gene target, an inflammatory pathway, a carcinoma model, or cell-type-resolved imaging, we can help design, formulate, and evaluate a suitable Gal-LNP strategy.
Challenge: A team developed galactose-LNPs carrying siRNA against a hepatic inflammatory target. Despite acceptable particle size, the 1.5 mol% lactobionic acid-cholesterol formulation achieved only 1.4-fold HepG2 uptake versus unmodified LNPs, with no improvement in gene knockdown.
Diagnosis: RCA120 lectin binding showed that less than half the fed galactose was surface-accessible. The formulation's 2 mol% PEG-lipid shielded the short ligand, while lactose competition indicated limited ASGPR-dependent uptake.
Solution: We ran a structured screen instead of adjusting one variable at a time. Three ligand architectures were compared—direct Gal-DSPE, Gal-PEG54-DSPE, and Gal-PEG2000-DSPE—each prepared at three densities, 0.25, 0.5, and 1.0 mol%, with the base formulation's PEG-lipid reduced to 1 mol%. All nine candidates plus controls were characterized for size, PDI, siRNA encapsulation, lectin binding, HepG2 uptake, and free lactose competition. The two strongest candidates were then tested in primary hepatocyte-like cells for uptake and knockdown of the client's target transcript.
Result: Gal-PEG2000-DSPE (0.5 mol%), introduced by post-insertion, produced 96 nm LNPs (PDI below 0.20) with over 85% siRNA encapsulation and threefold greater surface galactose display. HepG2 uptake reached fourfold above controls and fell 65% under lactose competition. Target-transcript knockdown improved 2.7-fold over the initial design.
Challenge: A biotechnology group sought galactose-targeted delivery of a poorly soluble anti-inflammatory compound. Co-assembly with Gal-DSPE disrupted particle formation, increasing particle size beyond 200 nm and PDI above 0.4. The particles aggregated within hours in serum-containing medium.
Diagnosis: Co-assembly caused the galactose-lipid and hydrophobic cargo to interfere with shell formation. Since the unmodified drug-LNP remained stable at 110 nm, post-assembly surface modification offered a more promising approach.
Solution: We screened four modification routes on the preformed drug-LNP. Co-assembly was retried with a rebalanced helper lipid ratio and still drifted above 160 nm. Post-insertion of Gal-PEG2000-DSPE micelles at 45 °C preserved particle size but caused measurable drug leakage at the elevated temperature. Post-insertion at 40 °C with a longer incubation time was then tested as a gentler variant. Thiol-maleimide coupling on maleimide-functionalized particles worked cleanly but added synthesis and purification steps the client preferred to avoid at this stage.
Result: Post-insertion at 40 °C yielded 112 nm particles (PDI 0.17), retained over 90% of the drug, and maintained particle size for 72 hours in serum-containing medium. Across three batches, size and galactose-density RSDs stayed below 8%. Hepatocyte uptake increased threefold over controls and decreased under lactose competition.
Flexible Ligand, Linker, and Lipid LibrariesWe maintain galactose, lactobionic acid, and clustered galactose ligand options, PEG spacers from short chains to PEG5000, and both phospholipid and cholesterol anchors, so projects are not boxed into a single conjugate structure.
One-Stop Support from Design to EvaluationLigand synthesis, LNP preparation, surface characterization, and cell-based evaluation happen under one project team, so formulation decisions made in the lab are informed by biological readouts from the same campaign.
Payload-Specific Formulation and Analytical SupportOur lipid nanoparticle formulation experience covers RNA, peptide, small-molecule, and imaging payloads, each with its own encapsulation strategy and analytical plan for payload integrity and retention.
ASGPR-Focused Hepatocyte Targeting EvaluationWe design competition assays, matched controls, and cell-model comparisons that distinguish receptor-directed uptake from nonspecific uptake, so targeting claims rest on evidence.
Customized Development and Comparative Formulation ScreeningProjects can start from a single feasibility study or a full comparative screen across ligand architectures, densities, and modification routes, with matched controls prepared for every candidate.
Galactose ligands displayed on an LNP surface can interact with the asialoglycoprotein receptor (ASGPR), which is highly expressed on many hepatocytes. This interaction may promote receptor-mediated binding and internalization, but it does not guarantee selective liver delivery or efficient release of the encapsulated cargo. Performance depends on accessible galactose groups, ligand density, spacer geometry, particle composition, and receptor expression in the chosen cell model. A sound evaluation compares galactose-modified particles with matched unmodified LNPs, includes free-galactose competition or receptor-blocking controls where suitable, and measures both cellular uptake and payload activity. Hepatocellular carcinoma models should be checked for actual ASGPR expression rather than assumed to be receptor-positive.
Galactose surface density determines how many carbohydrate groups are available for receptor recognition, but greater density is not always better. Sparse display may provide insufficient multivalent contact, whereas excessive galactose-lipid incorporation can alter particle assembly, crowd the surface, or interfere with formulation stability. PEG spacer length and neighboring PEG-lipids further influence whether galactose residues are exposed or shielded. The practical approach is to prepare a controlled density series and compare ASGPR-related binding, cellular uptake, particle size, polydispersity, zeta potential, payload retention, and functional response. The best design is one that improves delivery in the intended model without compromising essential particle attributes, rather than simply maximizing ligand density.
Galactose modification can be explored for siRNA, mRNA, antisense oligonucleotides, selected proteins or peptides, small molecules, and fluorescent tracking payloads, but each cargo presents a different formulation challenge. Nucleic acids require suitable ionizable lipid compositions and preservation of RNA integrity, while hydrophobic small molecules demand attention to partitioning, leakage, and release. Protein and peptide payloads may be sensitive to processing conditions. Surface galactose should therefore be optimized together with the core LNP rather than added as an isolated finishing step. Researchers should assess encapsulation or loading, stability, cellular uptake, and a cargo-specific functional endpoint, such as gene knockdown, reporter expression, or intracellular drug activity.
BOC Sciences provides project-specific support across galactose ligand selection, carbohydrate-lipid conjugate design and synthesis, surface functionalization, and LNP formulation development. Depending on the delivery objective, the work can examine phospholipid- or cholesterol-anchored galactose components, optional PEG spacers, co-assembly, post-insertion, or suitable surface coupling chemistry. Formulation studies can cover lipid ratios, loading conditions, ligand density, mixing parameters, and buffer exchange. Characterization may include particle size distribution, zeta potential, payload encapsulation, ligand presentation, and stability-related comparisons. For hepatocyte-oriented projects, the development plan can also include ASGPR expression assessment, receptor competition controls, cellular uptake analysis, and payload-specific functional readouts to support evidence-based candidate selection.
When galactose-LNPs show weak uptake or limited activity, BOC Sciences can help identify whether the bottleneck originates from ligand accessibility, receptor biology, particle attributes, or intracellular payload delivery. An investigation may compare receptor expression across relevant cell models, examine galactose exposure and PEG shielding, and test a defined series of ligand densities or linker lengths. In parallel, formulations can be checked for aggregation, encapsulation loss, premature leakage, and changes after processing. Matched unmodified LNPs and suitable competition studies help distinguish ASGPR-related effects from nonspecific uptake. The resulting data guide focused revisions to the galactose-lipid structure, LNP composition, preparation process, or delivery assay rather than relying on trial-and-error optimization.
